Zacks Company Profile for DNAPrint Genomics Inc. (DNAG : OTC) |
|
|
|
Company Description |
DNAPrint Genomics, Inc. offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer's proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents. The Company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. The Company provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers.
Number of Employees: |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
20 Day Moving Average: shares |
Shares Outstanding: 1,294.79 (millions) |
Market Capitalization: $0.13 (millions) |
Beta: -0.29 |
52 Week High: $0.00 |
52 Week Low: $0.00 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
% |
% |
12 Week |
% |
% |
Year To Date |
% |
% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
1621 W. UNIVERSITY PARKWAY - SARASOTA,FL 34243 USA |
ph: 941-366-3400 fax: 941-952-9770 |
dnap@dnaprint.com |
http://www.dnaprint.com |
|
|
|
General Corporate Information |
Officers
Richard Gabriel - President and Chief Executive Officer
Karen L. Surplus - Principal Accounting Officer
Hector Gomez - Director
Tony Frudakis - Director
- - -
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23324Q202
SIC: 8731
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding: 1,294.79
Most Recent Split Date: 7.00 (0.05:1)
Beta: -0.29
Market Capitalization: $0.13 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: - |
|
|
|
|